×

RNS Number : 8419L

Warpaint London PLC

24 April 2018

 

24 April 2018

Warpaint London plc

("Warpaint London" or the "Company")

Queen's Award for International Trade  

 

Warpaint London plc (AIM: W7L), the specialist supplier of colour cosmetics and owner of the W7 and Technic brands, is pleased to announce that Warpaint Cosmetics (2014) Ltd, a trading subsidiary of the Company, has been awarded the Queen's Award for International Trade for outstanding growth in overseas sales over the last three years.

The Queen's Awards for Enterprise recognises outstanding achievement by UK businesses in the categories of Innovation, International Trade and Sustainable Development. The awards are presented annually by HM The Queen, and are given for the highest levels of excellence demonstrated by a UK based company. The Queen's Award for International Trade recognises businesses that have achieved substantial growth in overseas earnings and in commercial success.

The Company has seen overseas sales increase steeply between 2014 and 2016 from £2.0 million to £10.4 million. Total growth in revenue over the period was 420% and overseas sales as a percentage of total sales rose year on year.

Commenting, Sam Bazini and Eoin Macleod, Joint Chief Executives of Warpaint, said: "We are extremely honoured and proud to be selected for a Queen's Award, and we would like to take this opportuntity to recognise the hard work and dedication of our employees, and efforts of our partners and distributors globally.

"To receive one of the most prestigious and internationally recognised awards for our international trade efforts reflects our strategy to continually progress as a business and drive the success of our brands, both domestically and overseas."

Enquiries:

Warpaint London PLC     Sam Bazini – Joint Chief Executive Officer Eoin Macleod – Joint Chief Executive Officer Neil Rodol – Chief Financial Officer	c/o IFC
Stockdale Securities Limited (Nominated Adviser and Broker) Antonio Bossi, Ed Thomas – Corporate Finance Fiona Conroy – Corporate Broking	020 7601 6100
IFC Advisory Limited (Financial PR & IR) Tim Metcalfe Heather Armstrong Florence Chandler	020 3934 6630

 

 

 

 

About Warpaint London plc

Warpaint London is a colour cosmetics business, based in Iver, Buckinghamshire. It is made up of two divisions: close-out and own-brand.  The second and larger own-brand division consists primarily of the Group's flagship brand, W7 – an extremely creative, design-focused cosmetic brand proposition with a focus on the 16-30 age range, delivering high-quality cosmetics at affordable prices. The W7 brand has grown organically since its inception in 2002 and now contains over 500 items which are sold into high street retailers and independent beauty shops across the UK, Europe, Australia and the US. In 2016, W7 was supplied to over 250 customers in more than 50 countries.

In 2017 Warpaint completed the acquisition of Retra Holdings Limited, a UK colour cosmetics business with a significant focus on the gifting market, principally for high street retailers and supermarkets including Boots, Superdrug and Asda. Retra owns three major brands: Technic, Body Collection and Man's Stuff, in addition to supplying white label cosmetics produced for several major high street retailers including Asda and Matalan.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAPGUCPCUPRGQW

Close

×

RNS Number : 4410L

Avanti Communications Group Plc

19 April 2018

 

 

19 April 2018

 

Avanti Communications announces its HYLAS 4 satellite has successfully reached its geostationary orbital position

 

Avanti Communications Group PLC (AIM: AVN), ("Avanti", the "Company") announces that following its successful launch on 5th April 2018, the HYLAS 4 Ka-band satellite has reached its geostationary orbital position on schedule.

The spacecraft is performing as expected and is in good health. The solar arrays, antenna pallets and electric propulsion thrusters have been successfully deployed. The in-orbit payload testing will begin shortly with service commencing as scheduled at the end of July

For further information, please contact:

Avanti Communications	Nigel Fox, Patrick Willcocks Tel: +44 20 7749 1600
Montfort	Nick Miles,  James Olley Tel: +44 203 770 7909
Cenkos Securities (Nomad)	Max Hartley, Nicholas Wells, Harry Hargreaves Tel: +44 207 397 8900
Redleaf Communications	Ralph Anderson +44 (0)20 3757 6883

 

 

 

 

 

 

Notes to Editors:

About Avanti Communications

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and partners in 118 countries, the network provides ubiquitous internet service to a quarter of the world's population. Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek.

 

Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and Ka-band spectrum in perpetuity that covers an end market of over 1.7bn people.

 

The Group has invested $1.2bn in a network that incorporates satellites, ground stations, datacentres and a fibre ring.

 

Avanti has a unique Cloud based customer interface that is protected by patented technology.

 

Avanti Communications is listed in London on AIM (AVN:LSE).

www.avantiplc.com 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLIFFDSEIALIT

Close

×

RNS Number : 2328L

N4 Pharma PLC

18 April 2018

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Commencement of Sildenafil Clinical Trial

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, is pleased to announce the start of its proof of concept clinical trial for its lead product, sildenafil, (the "Trial") following the completion of the validation of the reformulated sildenafil in accordance with the specifications submitted to the MHRA.

 

The Trial will comprise a four way crossover study in 12 healthy subjects comparing N4 Pharma's reformulated 100mg sildenafil to Viagra™ 50mg in both fed and fasted conditions. The Trial aims to measure the level of the drug in plasma achieved by N4 Pharma's reformulated product compared to Viagra™ over a 24 hour period.

 

The Trial is expected to take 8 to 10 weeks with provisional results data available in July 2018 with the final clinical study report expected at the end of August 2018.

 

The data gathered from the Trial will enable the Company to establish whether its reformulation has been sufficiently successful to allow N4 Pharma to prepare for a pre-IND meeting with the FDA towards the end of this year or whether further amendments to the reformulation may be required to optimise efficacy.

 

Nigel Theobald, CEO of N4 Pharma, commented: "We are delighted that N4 Pharma's first clinical trial has begun on our lead product, sildenafil. Slight delays in receiving the base ingredients to the reformulation, which had a knock effect on the validation of the product, has seen the timetable slip slightly. However, there should be no material impact on any move towards commercialisation assuming successful Trial results.

 

"The Board continues to believe that the improvements sought to be evidenced through the Trial will make our reformulation that much more attractive to both the end consumer and pharmaceutical partners in the final development and commercialisation of the drug in this highly lucrative market.

 

"We look forward to providing a further update as soon as we receive the full results which are expected in late August."

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)20 7601 6100
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

 

 

 

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines and therapeutics.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra™, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

Sildenafil Market Research:  

 

·     Market research undertaken by Black Swan Analysis in 2017 with clinicians in the UK and US who are currently prescribing sildenafil and competing products Vardenafil and Tadalafil which suggested that between 12% and 25% of clinicians in the UK (depending on the product) would switch patients to N4 Pharma's product and between 19% and 28% of clinicians in the US would do the same.

·     The size of the addressable market for sildenafil: the erectile dysfunction market had global annual sales of approximately $4.6 billion* in 2016 and is expected to fall to $3.2 billion by 2022 due to the anticipated patent expiry of Viagra™ and Cialis.

 

*Source: Evaluate Pharma

 

 

Glossary:

 

"MHRA"	The Medicines and Healthcare products Regulatory Agency
"Pre-IND"	Pre-Investigational New Product
"FDA"	Food and Drug Administration

 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLLFIRSRIDLIT

Close

×

RNS Number : 9426K

Solid State PLC

16 April 2018

 

 

Solid State plc

("Solid State", the "Group" or the "Company")

 

New Power Solutions distribution franchise won

 

Solid State plc (AIM: SOLI), the AIM listed manufacturer of computing, power and communications products, and value added distributor of electronic components, is pleased to announce a distribution franchise for VPT, a leading global provider of power conversion solutions for the rapid deployment of critical power systems in avionics, military and space applications.

 

Solid State Supplies has been chosen by VPT due to its extensive military and aerospace knowledge, its certification to AS9120, its existing industry client base and value added distribution capabilities.   The franchise is for exclusive rights to UK and Ireland and includes the transfer of the existing client base.

 

VPT has been selling into the UK market for 18 years to a loyal client base.  Its products do not overlap with the current Solid State Supplies range giving the opportunity to develop and expand the client's reach and product representation into relevant markets.

John Macmichael, Managing Director of Solid State Supplies, commented:

"The VPT product range complements the existing Solid State power operations.  They are an innovative, high quality supplier where we are confident that our approach will increase sales beyond the current run rate and broaden the customer base." 

 

For further information please contact:

 

Solid State plc	01527 830 630
Gary Marsh – Chief Executive Peter James – Group Finance Director	[email protected]
WH Ireland (Nominated Adviser & Joint Broker)	0117 945 3470
Mike Coe / Ed Allsopp (Corporate Finance) Jasper Berry / David Kilbourn (Corporate Broking / Sales)
finnCap (Joint Broker) Ed Frisby / Kate Bannatyne (Corporate Finance) Emily Morris / Rhys Williams (Corporate Broking / Sales)	020 7220 0500
Walbrook PR (Financial PR)	020 7933 8780
Tom Cooper / Paul Vann	0797 122 1972
	[email protected]

 

 

Notes to Editors:

 

Solid State plc (SOLI) is a leading value added group of companies providing specialist design-in and manufacturing services to those acquiring computing, power and communications products and electronic component services for use in harsh environments. 

 

Serving niche markets in oil & gas production, medical, construction, security, military and field maintenance, Solid State acts as both a component supplier to OEMs and bespoke manufacturer of specialist units to clients with complex requirements.

 

Headquartered in Redditch, Solid State employs over 200 staff across five sites.  Solid State operates through two main divisions: Solid State Supplies and Steatite.

 

Solid State was established in 1971 and admitted to AIM in June 1996.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUOABRWRASAAR

Close

×

RNS Number : 0738K

Avanti Communications Group Plc

06 April 2018

 

Avanti Communications Group Plc

Successful launch of HYLAS 4

Avanti Communications Group Plc ("Avanti") a leading satellite operator, providing Ka-band satellite data communications services across the UK, Europe, the Middle East and Africa, announces the successful launch of HYLAS 4 from Kourou, French Guiana on Ariane Flight VA242 on Thursday 5th April 2018.

The Ariane 5 rocket launched HYLAS 4 into the correct orbit on schedule. HYLAS 4 successfully separated from the Ariane 5 on time and telemetry was received by the control centre at the European Spaceport.

David Bestwick, Chief Technology Officer of Avanti Communications, said:
"I'm pleased to announce HYLAS 4 has been successfully launched and is operating under our control. The satellite will undertake a series of pre-planned in orbit acceptance tests over the coming months before we commence service for customers.

"HYLAS 4 will set the new standard of affordability, quality and flexibility to Internet Service Providers, Mobile Network Operators, Governments and other Satellite Operators. The High Throughput Satellite (HTS) has 64 Ka-band spot beams that complement our existing coverage across Europe, East and Southern Africa, as well as providing new capacity across West and Central Africa. Furthermore, HYLAS 4 has 4 steerable beams which can provide highly flexible capacity across Africa and Latin America."

 

For further information, please contact:

Avanti Communications	Nigel Fox, Patrick Willcocks Tel: +44 20 7749 1600
Montfort	Nick Miles,  James Olley Tel: +44 203 770 7909
Cenkos Securities (Nomad)	Max Hartley, Nicholas Wells Tel: +44 207 397 8900
Redleaf Communications	Ralph Anderson +44 (0)20 3757 6883

 

About Avanti

Avanti connects people wherever they are – in their homes, businesses, in government and on mobiles. Through the HYLAS satellite fleet and partners in 118 countries, the network provides ubiquitous internet service to a quarter of the world's population.

Avanti delivers the level of quality and flexibility that the most demanding telecoms customers in the world seek. Avanti is the first mover in high throughput satellite data communications in EMEA. It has rights to orbital slots and KA-band spectrum in perpetuity that covers an end market of over 1.7bn people. The Group has invested $1.2bn in a network that incorporates satellites, ground stations, datacentres and a fibre ring.

Avanti has a unique Cloud-based customer interface that is protected by patented technology. Avanti Communications is listed in London on AIM (AVN: LSE). www.avantiplc.com 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGUGDSSUGBGIL

Close

×

Neville Registrars is delighted to welcome Artilium plc as the newest addition to its list of client companies.

Artilium plc is a leading Mobile Virtual Network Enabler (MVNE) through its own state of the art Cloud platform.

Further information can be found on the Company's website: https://www.artilium.com/

Close

×

RNS Number : 3171J

Sativa Investments PLC

29 March 2018

 

 

 

Press release

Thursday 29 March 2018

Sativa Investments PLC

 

 ("Sativa" or "the Company")

 

Admission to NEX Exchange Growth Market having raised £1.1 million

 

Sativa Investments PLC, the UK's first medicinal cannabis Investment Vehicle, is pleased to announce that trading in its Ordinary Shares will commence at 8.00 a.m. today on the NEX Exchange Growth Market ("Admission"), under ticker SATI and ISIN number GB00BFX17474. 

 

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company's investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

 

Key highlights

 

·     On Admission the Company will have estimated net cash, including the Subscription proceeds, of £1,548,040 

 

·    The Company has raised £1,100,000 pursuant to the Subscription, to invest in and acquire control of certain target companies, although it may also consider acquiring non-controlling shareholdings in targeted Medicinal Cannabis businesses, following advice from the Company's Medical Cannabis Advisory Board. 

 

·     Sativa Investments will seek returns from the dynamic regulatory environment surrounding Medicinal Cannabis and will invest in well-placed businesses involved in production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis. 

 

·   While there are a large number of active cannabinoids found in Cannabis, Medicinal Cannabis has two cannabinoid components that can potentially treat human pain, disease and symptoms; tetrahydrocannabinol (THC) and cannabidiol (CBD). 

 

·     These two components of Medicinal Cannabis can potentially treat muscle spasticity and nausea, along with treating chronic pain by activating pathways in the central nervous system, which work to block pain signals through cannabinoid receptors.  As outlined by Leafscience, a provider of health and science information to Cannabis consumers and professionals, the product can also reduce the pain and discomfort of diseases such as cancer, glaucoma, liver disease, Parkinson's disease, traumatic brain injury, spinal cord injury and multiple sclerosis.  It is also believed to assist patients with post-traumatic stress disorder (PTSD), and relieves convulsion and inflammation. 

 

·     The Medicinal Cannabis sector is growing rapidly across the globe.  For example, the Medicinal Cannabis market in Ontario, Canada, is projected to climb from CA$379 million in 2018 to CA$2.22 billion by 2021, according to Brightfield Group projections, being an increase of 485 per cent increase in three years.  The demand for Medicinal Cannabis is soaring also in the Netherlands where, over the past five years, the number of doctor's prescriptions for Medicinal Cannabis grew by more than 400 per cent to over 50,000 in 2017, according to figures from the Foundation for Pharmaceutical Statistics (SFK).  The use of Medicinal Cannabis, which is only available with a doctor's prescription, took off in the Netherlands in 2016 with an increase of 75 per cent.  Jan Dirk Kroon of the SFK estimates that around 8,000 people in the Netherlands use Medicinal Cannabis. 

 

Management with strong track record

 

The Company's Board and Medicinal Cannabis Advisory Board have a combined 60 years' industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. 

 

Geremy Thomas, founder and CEO of Sativa, who together with family members has invested £785,000, £560,000 unconditionally at 0.25p per share and, pursuant to the Subscription, a further £225,000, said:  "Our decision to list on the NEX Exchange Growth Market makes both strategic and commercial sense as the market has great access to funding, regulation that fits Sativa's needs and the fact that NEX's Growth Market is an emerging market, which matches Sativa's start-up nature and culture.  We are delighted to see such high levels of investor demand and we now look forward to working with our shareholders and developing the Company. 

 

"The Company's Board and Medicinal Cannabis Advisory Board strongly believes that the dynamic regulatory environment of Canada's Medicinal Cannabis sector is the standard-bearer and will take off in key markets, as we are already seeing in the Americas and Europe, along with the strong groundswell of public support."

 

Directors Shareholdings

 

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are and will be as follows:

 

Director	Number of Ordinary Shares on Admission	% of Issued Share Capital
Geremy Thomas	224,000,000	52.97
Mark Blower	6,000,000	1.42
Noel Lyons	3,000,000	0.71

 

Notifiable Interests

 

In addition to the Directors holdings disclosed above, the Company has been notified or is aware of the following holdings which will, following Admission, represent more than 3 per cent. of the Issued Share Capital or voting rights of the Company:

 

Name	Number of Ordinary Shares on Admission	% of Issued Share Capital
Andrew McDonald	18,000,000	4.26
Clive Lonsdale	18,000,000	4.26
James Curtis	18,000,000	4.26
Acqam International	18,000,000	4.26
George Thomas	18,000,000	4.26
BMAK Investments Ltd*	18,000,000	4.26

*BMAK Investments Ltd participated in the Subscription, prior to publication of the Admission Document, through an investment of £100,000 at the Subscription Price, reference to which was inadvertently omitted from the Admission Document. 
 

The Company has thus raised £1,100,000 before expenses though the issue of 198,900,000 Ordinary Shares. The Company has net funds of approximately £1,548,040 after all expenses pertaining to admission to the NEX Exchange Growth Market.

 

Broker Option

 

The Directors have agreed to make available their allocated options for sale through Peterhouse should there be sufficient demand in the market following Admission and may also approve the issue of options to Peterhouse, at the discretion of the Directors, subject to demand and agreement with Peterhouse.

Total Voting Rights

Following the issue of the 198,900,000 Subscription Shares, the Company has 422,900,000 Ordinary Shares of 0.25p in issue, which also represents the total number of voting rights in the Company. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The definitions used in this announcement have the same meaning as they have in the Admission Document.

 

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

 

For further information please contact:

 

Geremy Thomas Founder & CEO Sativa Investments PLC +44 (0) 20 7971 1255 [email protected]	Mark Blower COO & Finance Director Sativa Investments PLC +44 (0) 20 7971 1255 enqui[email protected]
NEX Exchange Corporate Adviser Guy Miller Peterhouse Corporate Finance Limited +44 (0) 20 7469 0930 [email protected]
Financial PR, IR & general media enquiries Julian Bosdet / Dylan Mark /Alejandra Campuzano    Abchurch Communications +44 (0) 20 7469 4630

 

Notes to Editors

 

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company's investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

 

The Company's equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company's Board and Medical Cannabis Advisory Board have a combined 60 years' industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/ 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NEXFKFDPABKDDNB

Close

×

RNS Number : 1488J

LoopUp Group PLC

28 March 2018

 

 

 

 

 

28 March 2018

LOOPUP GROUP PLC

 

("LoopUp Group" or the "Group")

 

Expansion into Australia

 

Two new business acquisition 'Pods' being established

 

 

LoopUp Group plc (LSE AIM: LOOP), the premium remote meetings company, is pleased to announce its commercial expansion into the $275m Australian market1 with the formal opening of its Sydney office.

 

The Group has operated one of its four global datacenters in Australia since 2016 to serve its UK and US customers who have local operations in the region. That will now be augmented with a commercial office presence, where new business acquisition 'Pods' will target enterprises headquartered in Australia.

 

Steve Flavell, co-CEO of LoopUp, commented, "Australia has some very attractive attributes as a new market for LoopUp. There are several geographically-dispersed urban centres which drive conferencing activity, average selling prices are materially higher than the global average, and Sydney represents a wonderful focal point to develop into the Group's regional headquarters over time."

 

During a market research and testing phase over recent months, the Group has already contracted six customer wins, including a leading Australian private equity firm and a financial advisory and investment management group with over $100bn under management.

 

The Group has relocated five established members of its UK and US Pods to Sydney. Those employees will form the basis of two initial Australian Pods, which will be augmented with local graduate hires. During the first half of the current financial year, the two Pods will focus on building their pipelines to normalised Pod levels. The Group believes the Australian market is highly conducive to the LoopUp product proposition and expects growth and Pod performance to fall in line with normal UK and US pod levels thereafter.

 

1. Source: Wainhouse Research '2017 Asia Pacific Audio Conferencing Services Market Sizing' and '2017 Asia Pacific Personal Web-based Conferencing Services Market Sizing'

 

For further information, please contact:

 

LoopUp Group PLC	via FTI
Steve Flavell, co-CEO
Panmure Gordon (UK) Limited	+44 (0) 207 886 2500
Dominic Morley / Alina Vaskina (Corporate Finance)
Erik Anderson / Amy Sarra (Corporate Broking)
Numis Securities Limited	+44 (0) 207 260 1000
Simon Willis/Jonny Abbott (Corporate Finance)
Tom Ballard (Corporate Broking)
FTI Consulting, LLP	+44 (0) 203 727 1000
Matt Dixon / Harry Staight

 

 

About LoopUp Group plc

 

LoopUp (LSE AIM: LOOP) is a premium remote meetings solution. Streamlined and intuitive, LoopUp is built for business users and delivers the quality, security and reliability required in the enterprise. One-click screen sharing and integration with tools business people use every day, like Outlook™, make it easy for LoopUp users to collaborate in real time. LoopUp's award-winning SaaS solution doesn't overwhelm users with features, and doesn't require training. Over 2,000 enterprises worldwide, including Travelex, Kia Motors America, Planet Hollywood, National Geographic, and Subaru trust LoopUp with their remote meetings.

 

The Group is headquartered in London, with offices in San Francisco, New York, Boston, Hong Kong, Barbados and Australia, and is listed on the AIM market of the London Stock Exchange (LOOP). For further information, please visit: www.loopup.com.

Notes:

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCJRMFTMBJTBBP

Close

×

Neville Registrars is delighted to welcome Consolidated Growth Holdings Limited as the newest addition to its list of client companies.

Information on Consolidated Growth Holdings can be found on the Company website: http://www.cgh-limited.com/

Close

×

RNS Number : 5698I

EU Supply PLC

22 March 2018

 

22 March 2018

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Contract Win Denmark

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that the Group has been awarded a contract by the Danish Competition and Consumer Authority ("Authority") for delivery of CTMTM as SaaS and related services to the Authority. There is also an option for up to 6 other authorities in Denmark within the Ministry of Industry, Business and Financial Affairs to join the contract.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Fredrik Wallmark, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, Ed Thomas

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 8,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRASEUSAEFASEED

Close